2015 Fiscal Year Final Research Report
Study on super human dried amniotic membrane manufacture technology aiming at the manufacture of new materials for the regenerative therapy
Project/Area Number |
25460647
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Applied pharmacology
|
Research Institution | University of Toyama |
Principal Investigator |
Okabe Motonori 富山大学, 大学院医学薬学研究部(医学), 助教 (60283066)
|
Co-Investigator(Kenkyū-buntansha) |
吉田 淑子 富山大学, 大学院医学薬学研究部(医学), 准教授 (00171421)
相古 千加 富山大学, 大学院医学薬学研究部(医学), 助教 (10523889)
二階堂 敏雄 富山大学, 学内共同利用施設等, 理事・副学長 (50180568)
野村 義宏 東京農工大学, 農学部, 教授 (10228372)
林 京子 中部大学, 付置研究所, 研究員 (60110623)
|
Co-Investigator(Renkei-kenkyūsha) |
MIZUTA SYOUSHI 福井県立大学, 生物資源学, 准教授 (30254246)
DOKI YOSHINORI 富山大学, 大学院医学薬学研究部(医学), 講師 (90303221)
|
Project Period (FY) |
2013-04-01 – 2016-03-31
|
Keywords | ヒト組織利用研究 / ハイパードライヒト乾燥羊膜 / 抗生物質 / 抗菌効果 / 定量 / 国際特許 |
Outline of Final Research Achievements |
The human amniotic membrane (AM) has been widely used in ophthalmic surgery. However, it has never been explored that AM is effective for the release of impregnated drugs. Hyperdry-AM (HD-AM), glutaraldehyde cross-linked HD-AM (Glu HD-AM) and a solvent of poly-N-p-vinylbenzyl-D-lactonamide (PVLA) were all found not to cause irritation to the rabbit eye. Residual glutaraldehyde in Glu HD-AM was about 40 ppm (dry-weight basis). HD-AM (ACV/PVLA HD-AM) loaded Acyclovir (ACV; hydrophobic medicine) containing PVLA-bearing nanospheres (ACV/PVLA) was more effective against a herpes simplex virus-1 (HSV-1) eye infection model and its efficacy was dose- and volume-dependent. A combination of HD-AM and PVLA can be working as drug delivery system that may be possible to controlle the release of hydrophobic medicines.
|
Free Research Field |
境界医学、応用薬理学、ヒト組織利用研究、再生医学、
|